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Introduction
Pneumonia is the leading infectious cause of death globally (1) . Community acquired pneumonia (CAP) with sepsis (CAP+S) is common in the elderly, associated with high mortality and elderly survivors experience increased long-term morbidity, readmission and a reduced quality of life (2) . Most CAP+S are not caused by multi-resistant bacteria, even in vulnerable adults (3) . Given global concerns about antibiotic usage, new strategies are needed to improve patient outcomes.
Bacterial infections such as CAP require a rapid but proportionate neutrophil response, initially proinflammatory and bacteriocidal and then anti-inflammatory to promote tissue repair. In health neutrophils maintain an exquisite, environment-dependent balance between aggression or quiescence and mortality and morbidity are seen with either inappropriately exaggerated or inhibited responses (4) . In sepsis, both heightened and reduced neutrophil functions are linked to mortality depending on the timing of these cellular responses. For example, reduced neutrophil extracellular trap formation (NETosis) on admission (potentially representing an inadequate response) and increased NETosis on day seven of the admission (potentially representing an overly aggressive, sustained pro-inflammatory response) are all associated with poorer patient outcomes (5, 6) .
Host age impacts on neutrophil functions. In vitro, neutrophils isolated from older adults without an acute infection or inflammatory challenge display reduced neutrophil migratory accuracy (7) , phagocytosis (8) and NETosis (9) , although degranulation appears increased (7) . Our previous data suggest that during infection in older adults, some but not all functions are blunted further.
Migratory accuracy is reduced during respiratory infections which progresses to migratory failure during sepsis; remaining impaired six weeks after the initial infective event (10) . Phagocytosis of E.
Coli (11) and NETosis to phorbol myristate acetate (PMA) (5) appears preserved, reactive oxygen species (ROS) generation may increase (12) but these functions are compromised in severe sepsis. A reduced ability to target bacteria with enhanced degranulation/ROS would potentially increase bacterial invasion, local inflammation and by-stander tissue damaging, which is in keeping with the higher burden of severe sepsis and end-organ damage experienced by this group (13) .
There is great interest in using HMG-CoA reductase inhibitors ("statins") to improve the immune response to infections, but studies have discordant results. In vitro and in a proof of concept clinical trial, simvastatin improved the migratory accuracy of neutrophils from older people at therapeutically relevant concentrations (10, 14) . In vitro high dose simvastatin increased NETosis (15) while in vivo, simvastatin reduced NETosis in a murine model (16) . In observational studies and during milder sepsis events, statins have been associated with improved patient outcomes (17) . However, most studies of sepsis in ventilated patients on critical care units have shown no benefit (18) although a recent post-hoc analysis has identified a group of responders (19) . (20) . Most in vitro studies do not explicitly state whether they have used the pro-drug but activated it or used the active drug and therefore discordant results may represent off-target effects. Current human studies suggest positive outcomes will be limited to older patients given high-dose statins early during a less severe infection event (for example, pneumonia which does not require treatment in critical care) (17, 21) or those taking statins prior to the infective insult (22, 23) .
Statins have been prescribed in critically ill patients (24) but some patients experience serious side effects (25) . Concerns have been raised about interactions between statins and medications which inhibit the drug-metabolizing enzyme cytochrome P450 3A4 (26) , including clarithromycin, commonly prescribed for patients with CAP. However, a recent study found only a small increase in the relative risk of adverse events during co-prescription (27) .
We hypothesised that simvastatin added to the standard treatment for older patients with CAP+S treated outside of critical care would improve neutrophil responses to infection (NETosis and migratory accuracy) and would be well tolerated and safe in this elderly population. This proof of concept experimental medicine study had three aims:
1.
To determine if treatment with simvastatin altered neutrophil function in older patients with CAP+S.
2.
To determine the safety and tolerability of high-dose simvastatin in CAP+S for seven days.
3.
To ascertain if simvastatin had effects upon both clinical and laboratory outcomes relevant to CAP+S.
Methods

STUDY DESIGN
The trial schedule is shown in figure 1.
Patients were eligible if they fulfilled the criteria described in table 1. The British Thoracic Society guidelines for CAP requires patients to have >3 of cough, sputum production, breathlessness, pleuritic chest pain, haemoptysis, fever, headache; signs consistent with pneumonia on chest auscultation with a chest radiograph of consolidative changes for which there is no other clinical explanation (28) . Patients also had to meet the 2012 Surviving Sepsis Campaign Guidelines (29) participants and researchers were blinded to treatment until all study assays were complete and oneyear survival data was collected.
END POINTS
Primary outcome
The primary outcome was change in NETosis at Day 4 compared to Day 0.
Secondary outcomes were:
1. Change in neutrophil migratory accuracy at Day 4 compared to Day 0 2. Safety and tolerability of simvastatin. The SOFA score is a well-validated scoring system used to determine the extent of organ failure. Six individual organs systems are assessed (respiratory, cardiovascular, liver, kidney and neurological and haematological) with a score of 0 to 4 given for each organ with a maximum score of 24. Higher SOFA scores indicate a great burden of organ failure.
Exploratory and post-hoc analysis
Change in inflammatory cytokines and neutrophil: lymphocyte ratios formed exploratory endpoints.
Since the conception of this study the SEPSIS-3 (30) definitions were published. A post-hoc analysis of the key neutrophil functions between the placebo and simvastatin groups were performed, classifying recruited patients by the presence or absence of SOFA≥2 in the presence of presumed/confirmed infection.
In addition, a composite secondary end-point combining re-admissions and survival at 180-days and 1-year, termed "hospitalization-free survival" was calculated as part of a post hoc analysis. This patient centred outcome (31, 32) was included following patient and public work groups (see online supplement) and was calculated in the following manner: deaths were confirmed at 180 and 365 days following enrolment by contacting the participants general practitioner (GP, primary healthcare doctor) and searching public records. Hospitalizations in the same period were assessed through electronic patient records, discussion with the GP and the patient (where possible). Time in days to the first re-admission or death was compared between groups.
NEUTROPHIL STUDIES
Full methods for all neutrophil studies are detailed in the online supplement, including validation of 100nM fMLP to generate NETosis in a CAP+S population.
Neutrophils were isolated from whole blood as described (33) . The neutrophils (> 97% viable by exclusion of trypan blue and >95% pure) were re-suspended in buffer (RPMI 1640 medium (Sigma, UK) containing 0.15% bovine serum albumin (Sigma, UK)).
NETosis
NETosis was performed on freshly isolated CAP+S neutrophils, stimulated with fMLP 100nM to represent a pathologically relevant stimulus, and 25nM Phorbol-Myristate-Acetate (PMA), used as a positive control, or vehicle control (RPMI 1640 supplemented with 2nM L-Glutamine, 100U/ml Streptomycin and 100ug/ml Penicillin [GPS]) (Sigma-Aldrich for all) as described (9) . Validation for fMLP as a stimulus in CAP+S patients is given in the online supplement and these studies also informed power calculations.
Neutrophil migration
Migration was assessed using an Insall Chamber (Weber Scientific International Ltd, Teddington, UK)
as previously described (34) .
Neutrophil apoptosis
The percentage of apoptotic neutrophils was determined using the binding of Annexin-FITC (ThermoFisher Scientific, UK) protein to cell surface, as previously described (9) and as presented in the online supplement.
Neutrophil elastase activity
Aα-Val 360 is a neutrophil elastase (NE) specific fibrinogen degradation product and therefore a surrogate marker of NE activity in vivo. Aα-Val 360 was measured in plasma using a highly specific enzyme-linked immunosorbent assay-based assay; as described (35) .
WHITE CELL RESPONSE AND CRP
Differential white cell count (WCC) and C-reactive protein (CRP) were measured by the NHS laboratories and reported as a standard clinical assessment. From these, total WCC and neutrophil to lymphocyte ratio were compared from Day 0 to Day 4.
SYSTEMIC CYTOKINES
Plasma cytokines were measured using the Luminex multi-analyte assay kit (Bio Techne, Abingdon, UK) as per manufacturer's instructions and compared from Day 0 to Day 4.
STATISTICAL ANALYSIS
Statistical analyses were carried out using PASW v18.0 (Chicago, IL, USA). Non-parametric tests were used throughout. The assessments for neutrophil functions (NETosis and Chemotaxis) and neutrophil elastase activity were performed by calculating the change in these functions between day 4 and baseline to provide a measure of the treatment effect in each group. Power calculations are provided below. All statistical tests are listed for each comparison, were 2 sided with p<0.05 accepted as statistically significant. All clinical outcomes including safety monitoring, side effects and adverse event reporting were based on intention to treat. All cellular data for Day 0 is reported in text. For SOFA scores and non-clinical outcomes, the change from day 0 to day 4 was compared in primary and secondary endpoints, and so those without data for Day 4 were excluded, but drop outs were similar in terms of number and reason for both groups (see Figure 2 ). There was no adjustment for multiple comparisons but all results are reported and all primary and secondary outcomes and comparisons were planned a priori.
Power calculations
Our preliminary studies suggested that mean NETosis from systemic, isolated neutrophils from CAP patients on admission was 7500 arbitrary units (AU) (SD 2,432). 18 patients in each arm would be 
RESULTS
This study was a single-centre randomized, double-blinded, placebo-controlled trial. The initial protocol, registered on the European Clinical Trials Database (EudraCT Number: 2012-003343-29) required amendment to secure ethical approvals, and was published (36) , however a further amendment was undertaken after the start of recruitment. An abridged version of the final protocol is available in the online supplement. The trial and all amendments were approved by Yorkshire and Humber Ethics Committee (REC 12/YH/0375) and patients with CAP+S were randomised to receive simvastatin 80mg or placebo (both manufactured by Sharp Clinical Services Ltd (Crickhowell,UK)) once daily for 7 days or until hospital discharge, whichever sooner. Patients were followed up for 12-months to assess readmission rates and mortality. The trial was ended once recruitment targets were met.
In total 62 patients were recruited from one centre (Queen Elizabeth Hospital, Birmingham, UK) with clinical and safety data analysed on intention-to-treat between November 2013 to January 2016 with 1-year follow-up completed in January 2017. A modified consort diagram is given in figure 2 . Table 2 describes patient demographics. There were no differences in baseline demographics between patients in the intervention or placebo group. Co-morbidities are described in table S1 of the online supplement.
Primary Outcome: Neutrophil NETosis is reduced in patients taking Simvastatin.
There were no differences in Day 0 fMLP associated NETosis between the two groups, (median (IQR), This confirmed that oral simvastatin reduced NETosis following in vitro activation with a pathologically relevant trigger, with studies suggesting NETosis can differ between a physiological/pathological versus non-physiological/pathological (PMA) trigger (37) .
Neutrophil migratory accuracy improves in patients taking simvastatin.
There were no differences in Day 0 chemotaxis towards CXCL8 at baseline between the two groups 
Simvastatin is not associated with changes in the neutrophil: lymphocyte ratio count
Neutrophil: Lymphocyte ratio (NLR) is considered a biomarker of adverse outcome in sepsis and may be reduced by statin therapy (38) . For both simvastatin and placebo treated groups, there was a Simvastatin was not associated with changes in CRP or in other measured systemic cytokines.
There were no differences in Day 0 or Day 4 CRP or systemic cytokine concentrations between the two groups. Further, there were no differences in the change between Day 0 and Day 4 CRP or systemic cytokine concentrations between the groups (see online supplement). Electronic hospital records demonstrated good compliance with the study drugs with only 3 patients missing one dose each of the study drug/placebo (2 for placebo and 1 for simvastatin).
Tolerability and Safety
Clinical Outcomes
SOFA scores were generally low, as expected in this ward-based cohort of patients with CAP. There was a greater change (reduction) in SOFA score (Day 4 -Day 0; median (IQR)) in patients receiving simvastatin, -2 (-3 to -1) compared with those receiving placebo -1 (-2 to 0), p<0.026 Mann Whitney U: see figure 6 . All patients treated with simvastatin showed a reduction in SOFA score, whilst three patients in the placebo group showed an increase in SOFA score.
There were no differences in hospital length of stay or readmissions between groups. Placebo treated patients had higher mortality at 30, 180 and 365 days but this did not reach significance using Fisher's Exact test (see Table 4 ). In survivors, up to one year after discharge, there was no difference in the time without readmission to hospital in the first year (median (IQR) Simvastatin, 365 days (IQR 103 to
Severity of infection according to SEPSIS-3 criteria
Patients' severity of infection was stratified in a post-hoc analysis according to SEPSIS-3 definitions and neutrophil functions of NETosis and chemotaxis assessed. A total of 27 (44%) patients met the SEPSIS-3 definition (SOFA ≥2), simvastatin (n=16) and placebo (n=11) groups with no differences in patient characteristics between the two groups (see table S2 in the online supplement). None of the patients recruited to the trial had septic shock but two were moved to critical care during their hospital stay, neither of whom met the Sepsis 3 definition of septic shock.
There was no difference between NETosis at Day 0 in SEPSIS-3 +ve and SEPSIS-3 negative (SEPSIS-3 - 
Discussion
This proof of concept study is the first report of a therapeutic intervention impacting on neutrophil functions and clinical endpoints in older patients with CAP+S. At Day 4, simvastatin was associated with a reduction in neutrophil NETosis (following physiological stimulation), reduced systemic neutrophil elastase activity, improved neutrophil migrational accuracy and a small reduction in SOFA score. Furthermore, high-dose simvastatin was safe and tolerated with the co-prescription of clarithromycin. Although mortality and time to readmission or readmission rates were not different between groups, a post hoc analysis suggested simvastatin treatment was associated with increased hospitalization-free survival, an endpoint highlighted as important by patients and included in clinical trials (40) .
Pneumonia hospitalizations are predicted to double by 2040 (41) . Poor outcomes in the elderly are rarely associated with antibiotic resistance (42) suggesting new antibiotic provision may not improve survival. The World Health Organization has called for new strategies for infectious diseases (43) . This proof of concept study suggests modifying neutrophil function may improve outcomes during acute infection, but also highlights the complex, stimulus-specific and dynamic nature of neutrophil responses in sepsis.
Here, we interpret a reduction in NETosis and NE activity and an improvement in neutrophil migratory accuracy at Day 4 as positive, anti-inflammatory events. The optimal neutrophil response to infection should be proportionate to the level of threat and will vary during the course of the illness, from infection onset (where responses should be pro-inflammatory and bacteriocidal) into recovery (where these pro-inflammatory responses should diminish). Sustained NETosis is associated with endovascular damage and coagulopathy in human and murine sepsis (44, 45) . Reduced migratory accuracy has been associated with poor patient outcomes and increased tissue damage due to obligate proteolysis (34, 46) . Fibrinogen degradation is a marker of systemic neutrophil elastase activity.
Neutrophil elastase has pleiotropic pro-inflammatory effects that may drive tissue injury including activation of endothelial and epithelial cells, degradation of extracellular matrix components (47) ,
cleavage of receptors and anti-inflammatory proteins (48) (49) (50) and enhancing oxidative stress (51) .
Studies suggest CAP bacterial eradication is seen in approximately 3 days with appropriate treatment (52, 53) and negative outcomes are rarely associated with antibiotic failure but are associated with dysregulated immune responses. We propose that blunted pro-inflammatory neutrophil responses at Day 0 (as seen in SEPSIS-3 positive patients), or inappropriately sustained proinflammatory responses at Day 4 should be considered pathological. There is some evidence to support this. For example, although sustained NETosis is implicated in end organ damage in sepsis (54) blunted NETosis at onset is associated increased mortality (5, 55) . Similarly, both increased migratory or ROS responses and failure of neutrophil migration and ROS have been implicated in poor outcomes (34, 56) . In this study we aimed to normalise functions to their "optimal" state at Day 4, which we would assume to be that of a less inflammatory state compared with Day 0.
The pleotropic effects of statins have led to studies in sepsis and ARDS but evidence of efficacy is controversial. In most cases, phase 3 trials have been negative in patients recruited within critical care units (57) although recently a group of "hyper-inflammatory" ARDS patients showed benefit (19) , supporting our data suggesting that simvastatin has an "anti-inflammatory" effect in vivo. Most previous studies included a wide range of patients and diseases and many utilised "low" statin doses.
We and others have described how the patient group (older), severity of the host insult (milder), dose of statin (higher) and timing of the intervention (early) are likely to impact the effectiveness of the therapy (21) . Concordantly, a recent meta-analyses (58) suggested that statins reduced mortality after non-severe but not after severe pneumonia. In addition, our phase II ASEPSIS study recruited wardbased patients with sepsis and demonstrated that atorvastatin could prevent the progression of sepsis to severe sepsis (17) . Our study did not identify changes in systemic pro-inflammatory mediators but was not powered for this endpoint (which was considered exploratory), therefore further studies could assess whether a greater statin response is seen in patients with a more pro-inflammatory systemic read out, as recently reported (19) .
Our patient cohort was elderly with significant medical co-morbidities but these were well matched between groups. The Kaplan Meier curves for hospitalization-free survival diverged from approximately 20 days post enrolment, suggesting that simvastatin had a long-term beneficial effect, but the mechanism for this is unclear and further studies are needed to explore this. However, statins are known to have multiple epigenetic effects on a wide number of cell types even following short term exposure (59) and statins can affect immune cell signalling, gene transcription, epigenetic modification and metabolism both in mature and immature progenitor cells (60) . It is possible that the long-term effects of a short course of simvastatin might be through neutrophil progenitors, but this is speculation.
The current study has important limitations. The study was not powered for any of the clinical endpoints included, and so these must be interpreted with caution. We could not explore differences in patient's responses to simvastatin which might inform who would gain the most clinical benefit from adjuvant therapy and further trials should focus on this. Although simvastatin was considered safe and well tolerated in this group, the study was not powered to assess differences in CK or liver dysfunction and a larger study is needed to assess safety (as well as efficacy) further. This study assessed ALT only for liver dysfunction, but this has been found to be sufficient in a recent study of statins (61) . Due to practical constraints on laboratory processing, not all neutrophil functions could be studied nor did we assess the mechanism of effect of simvastatin on neutrophil functions.
Furthermore, responses to infections involves crosstalk between all facets of the immune system but this was not assessed and requires clarification. Our understanding of neutrophil responses, including NETosis are evolving. In many studies, PMA is used as the gold standard for maximal NET generation, however we chose fMLP as this represents a physiologically-relevant stimulus. We demonstrate that fMLP is sufficient to cause NETosis in systemic neutrophils from the inflammatory environment of sepsis and there are studies highlighting important differences in NETosis triggered by biologically relevant stimuli versus PMA (37) . Unlike migration, the assay for NETosis only included live cell imaging in a proportion of patients, and therefore our indirectly measured assay, although included in many publications, should be considered a limitation. Also, the change in NETosis seen in this study between Day 0 and Day 4 was less than predicted in our a priori power calculations. It is difficult to judge what the minimally important effect size is for a cellular function and this may be dependent on how much NETosis is required to contain bacteria in a specific setting. However, although the actual change in NETosis was relatively small, it is notable that a number of cellular functions seemed to change in a manner which might be associated with less tissue damage to the host at Day 4 (improved neutrophil directional migration, a reduced signal of proteinase activity and reduced NETosis at Day 4).
Despite these limitations, this trial is of importance. This study highlights that it is possible to conduct a RCT in elderly and acutely unwell patients outside a critical care setting. The trial also is the first to demonstrate improvements in neutrophil functions which are impeded with age and infection, and link these to clinical benefit. The study provides further clarity on the potential role of simvastatin during infections, including which patients (older), when (early and mild), at what dose (high) and for how long (7 days). It also provides reassurance that high dose simvastatin is safe.
There is now a pressing need for a multi-centred trial in a ward-based cohort of pneumonia patients, and to consider a similar approach in other infections. These trials should clarify both efficacy (using both mortality and readmission, which appeared of particular importance to patients) and risk, and should also try to determine whether the effect on neutrophil function is indeed a critical function of response or whether other cellular mechanisms are equally important.
FIGURE LEGENDS Figure 1: The study schedule
Legend. Patients were identified and recruited within 48 hours of admission. Baseline information (clinical assessment, symptoms, blood samples for neutrophil isolation, clinical studies [including cholesterol, renal function, liver function, a full blood count, clotting status and creatinine kinase] and inflammatory studies) were taken just prior to randomisation. Post randomization, patients were prescribed 80mg Simvastatin or placebo once daily for seven days. Medications were dispensed by ward nursing staff and tablet ingestion noted in an electronic prescribing log. On Day 4 (after the ingestion of the fourth tablet) clinical and safety data were collected alongside blood tests for neutrophil studies, safety information and inflammatory studies (as described above). These assessments were repeated 7 days after the ingestion of the first tablet (after 7 doses of the tablet), if patients remained an inpatient. Patients and their general practitioners were contacted and electronic health records were analysed at 12 months following recruitment to gather data on readmission to hospital and survival.
Figure 2 Modified Consort Diagram of Trial endpoints.
Legend. 237 patients were screened with CAP+S but 28 did not provide consent or assent, 111 did not meet inclusion criteria, and 36 met exclusion criteria. 62 patients were recruited to the study and all were followed up for clinical endpoints at 12 months using an intention to treat analysis with consent even if they withdrew from the study. Patients who did not complete simvastatin or placebo therapy to Day 4 endpoints or then to day 7 endpoints due to study withdrawal or hospital discharge were not included in neutrophil functional studies as the study compared changes in function from baseline in a paired analysis. D/C = discharged due to clinical recovery. 
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